Last updated: April 27, 2023
Sponsor: Andrew Krystal
Overall Status: Active - Recruiting
Phase
N/A
Condition
Affective Disorders
Depression (Major/severe)
Mood Disorders
Treatment
Stimulation-ON Active Control
Stimulation-OFF
Stimulation-ON
Clinical Study ID
NCT04004169
17-23724
Ages 22-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 22-70
- Meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnosticcriteria for Major Depressive Disorder (MDD) without psychosis based on a StructuredClinical Interview for DSM-V (SCID) with current episode ≥ 2 years that is treatment-resistant (4 adequate trials (including ECT), 3 classes of medications, oneaugmentation strategy, psychotherapy) as measured by the antidepressant treatmenthistory form (ATHF).
- Failed electroconvulsive therapy (ECT) due to inability to achieve sustained response (2 failed attempts to discontinue ECT treatment) or discontinued due to intolerableside effects.
- Has MADRS score of > 26 at both baseline and screening visit
- The presence of variability on repeated administrations of MDD rating scales (minimumof 2-point variation on the HAMD-6 administered 3 times a day for 3 days), which isrequired for the identification of a neural biomarker.
- If patient is on a regimen of psychotropic medication, no changes in this regimenshould be made during the 4 weeks prior to entry into and the duration of the study.
- Willing and able to undergo invasive brain recording/stimulation study
- Willing and able to attend multiple research visits and perform at-home researchprotocol
- Willing and able to provide informed consent
- Ability to speak and read English
Exclusion
Exclusion Criteria:
- Meets DSM-V criteria for a psychotic disorder, eating disorder, panic disorder,posttraumatic stress disorder, bipolar disorder, obsessive compulsive disorder, ticdisorder, or another comorbid psychiatric disorder other than MDD or generalizedanxiety disorder based on a SCID
- Generalized anxiety disorder is the primary DSM-V disorder during the current MDDepisode
- Active suicidal ideation with intent and plan as defined by a score of 5 on theColumbia-Suicide Severity Rating Scale (C-SSRS)
- History of suicide attempt requiring hospitalization in previous 2 years.
- Meets criteria for alcohol or substance abuse or dependence (other than caffeine) inprevious 6 months, determined by the SCID
- Has a personality disorder based on the investigator's assessment that theinvestigator believes will adversely impact subject compliance or safety
- Fibromyalgia or chronic fatigue syndrome
- Current condition requiring chronic narcotic use
- History of traumatic brain injury, another neurological disorder, or developmentaldelay
- History of seizures
- MRI (done within one year of the first visit) with significant abnormalities
- Previous ablative intracranial surgery or previously implanted deep brain stimulationsystem or any previously implanted device treatment involving brain stimulation
- Implantable hardware not compatible with MRI or with the study
- Major medical co-morbidities increasing the risk of surgery including severe diabetes,major organ system failure, history of hemorrhagic stroke, need for chronicanticoagulation other than aspirin, active infection, intracranial space occupyinglesion, increased intracranial pressure, cardiovascular accident within the lastmonth, aneurysm/abnormality, retinal detachment, unstable cardiovascular disease (recent myocardial infarction, severe ischemia, severe or uncontrolled hypertension),immunocompromised state, or malignancy with < 5 years life expectancy
- Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and aftersurgery. - Patients taking these medications will need to discuss the need/risk ofcontinuing these medications with their physicians and the PI or study personnel maycontact the treating physician(s) to discuss the risks ofanticoagulation/antiaggregation therapy discontinuation
- Coagulopathy. Patients will be excluded unless assessed and cleared by hematology
- Allergies or known hypersensitivity to materials in the NeuroPace RNS® System (i.e.titanium, polyurethane, silicone, polyetherimide, stainless steel)
- Subject lives alone without possibility of caregiver support post-hospital stay
- Inability to comply with study follow-up visits
- Women who are pregnant, plan to become pregnant, or breast feeding
- Inability to speak and/or read English
- Inability to give consent
- Significant cognitive impairment or dementia (MoCA < 25)
- Likely to require ECT during the course of the study
Study Design
Total Participants: 12
Treatment Group(s): 3
Primary Treatment: Stimulation-ON Active Control
Phase:
Study Start date:
July 18, 2019
Estimated Completion Date:
June 28, 2035
Study Description
Connect with a study center
University of California, San Francisco
San Francisco, California 94143
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.